Replimune Group, Inc.

REPL Healthcare Biotechnology

In the quarter to June 2026, EPS grew 24.2%, free cash flow grew 5.04% and total debt rose 52.6%, each against the same quarter a year earlier.

10.86 0.89 −7.57%
Market cap
$1.1B
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Current Ratio

+8 more quarters

6.31 5.60 4.79 5.23
Net Debt/EBITDA
2.99 2.80 2.25 1.34
Debt/Equity
0.26 0.33 0.63 1.00
Free Cash Flow per Share
(0.90) (0.72) (0.61) (0.78)
Book value per Share
2.87 2.28 1.79 1.09
Free Cash Flow
(82.55) (66.09) (56.17) (75.73)
Other line items

Show all line items

Columns are period end dates